[Aspergillosis in pulmonary transplantation].
BACKGROUND
Fungal infections are a frequent cause of morbidity an mortality in transplant recipients. Aspergillus spp. is an ubiquitous fungus capable of producing diverse clinical entities with varying severity.


OBJECTIVE
To study the incidence and severity of Aspergillus spp. infections in lung transplantation, analysing the different clinical presentations and response to antifungal drugs.


METHODS
A review was made of the clinical histories of all patients undergoing lung transplantation who developed positive Aspergillus spp. cultures in our centre between June 1991 and December 1996.


RESULTS
Eleven of 49 transplanted patients (22%) developed Aspergillus spp. infections. Four patients presented invasive aspergillosis forms and 7 tracheobronchitis. In spite of antifungal treatment 3 patients (30%) died of invasive aspergillosis as a direct consequence of the infection. Of the 7 patients with tracheobronchitis, 2 were ulcerative and 1 pseudomembranous, all responded to antifungal treatment. Three patients (10.3%) developed Aspergillus spp. infections despite prophylaxis with itraconazole.


CONCLUSIONS
Invasive aspergillosis in the immediate posttransplant period was mortal despite treatment. As opposed, aspergillar tracheobronchitis have been overcome using combined treatments of liposomal or lipidic amphotericin, itraconazole and nebulised amphotericin.
de Pablo
A
A
Servicio de Neumología, Clínica Puerta de Hierro, Madrid.
Ussetti
P
P
Cruz Carreño
M
M
Lázaro
T
T
Ferreiro
M J
MJ
López
A
A
Mendaza
P
P
Estada
J
J
D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D001991:Bronchitis / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000009:adverse effects; D015994:Incidence; D017964:Itraconazole / Q000008:administration & dosage / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D016040:Lung Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control; D011292:Premedication; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology; D014136:Tracheitis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology; D016896:Treatment Outcome
D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B